vs

Side-by-side financial comparison of FEDERAL AGRICULTURAL MORTGAGE CORP (AGM) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Tarsus Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($151.7M vs $107.5M, roughly 1.4× FEDERAL AGRICULTURAL MORTGAGE CORP). On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 6.1%). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 7.1%).

The Federal Agricultural Mortgage Corporation, also known as Farmer Mac, is a stockholder-owned, federally chartered corporation established by the U.S. Congress in 1988 under the Agricultural Credit Act of 1987. It was created to establish a secondary market for agricultural real estate and housing mortgage loans, to increase liquidity and the availability of long-term, stable credit for farmers, ranchers, and rural communities.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

AGM vs TARS — Head-to-Head

Bigger by revenue
TARS
TARS
1.4× larger
TARS
$151.7M
$107.5M
AGM
Growing faster (revenue YoY)
TARS
TARS
+122.3% gap
TARS
128.4%
6.1%
AGM
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
7.1%
AGM

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AGM
AGM
TARS
TARS
Revenue
$107.5M
$151.7M
Net Profit
$-8.4M
Gross Margin
Operating Margin
56.3%
-5.3%
Net Margin
-5.5%
Revenue YoY
6.1%
128.4%
Net Profit YoY
63.8%
EPS (diluted)
$3.69
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AGM
AGM
TARS
TARS
Q4 25
$107.5M
$151.7M
Q3 25
$104.0M
$118.7M
Q2 25
$102.6M
$102.7M
Q1 25
$94.3M
$78.3M
Q4 24
$101.3M
$66.4M
Q3 24
$90.3M
$48.1M
Q2 24
$89.9M
$40.8M
Q1 24
$93.7M
$27.6M
Net Profit
AGM
AGM
TARS
TARS
Q4 25
$-8.4M
Q3 25
$55.0M
$-12.6M
Q2 25
$54.8M
$-20.3M
Q1 25
$49.7M
$-25.1M
Q4 24
$56.5M
$-23.1M
Q3 24
$49.8M
$-23.4M
Q2 24
$47.1M
$-33.3M
Q1 24
$53.7M
$-35.7M
Operating Margin
AGM
AGM
TARS
TARS
Q4 25
56.3%
-5.3%
Q3 25
64.1%
-12.2%
Q2 25
63.8%
-21.6%
Q1 25
66.9%
-33.5%
Q4 24
67.5%
-36.8%
Q3 24
69.0%
-52.3%
Q2 24
65.9%
-81.6%
Q1 24
72.8%
-136.5%
Net Margin
AGM
AGM
TARS
TARS
Q4 25
-5.5%
Q3 25
52.9%
-10.6%
Q2 25
53.4%
-19.8%
Q1 25
52.6%
-32.1%
Q4 24
55.8%
-34.8%
Q3 24
55.2%
-48.7%
Q2 24
52.4%
-81.6%
Q1 24
57.4%
-129.4%
EPS (diluted)
AGM
AGM
TARS
TARS
Q4 25
$3.69
$-0.17
Q3 25
$4.44
$-0.30
Q2 25
$4.48
$-0.48
Q1 25
$4.01
$-0.64
Q4 24
$4.62
$-0.57
Q3 24
$3.86
$-0.61
Q2 24
$3.68
$-0.88
Q1 24
$4.28
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AGM
AGM
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$417.3M
Total DebtLower is stronger
$30.8B
$72.4M
Stockholders' EquityBook value
$1.7B
$343.4M
Total Assets
$35.4B
$562.2M
Debt / EquityLower = less leverage
17.93×
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AGM
AGM
TARS
TARS
Q4 25
$417.3M
Q3 25
$401.8M
Q2 25
$381.1M
Q1 25
$407.9M
Q4 24
$291.4M
Q3 24
$842.1M
$317.0M
Q2 24
$923.0M
$323.6M
Q1 24
$745.1M
$298.5M
Total Debt
AGM
AGM
TARS
TARS
Q4 25
$30.8B
$72.4M
Q3 25
$29.2B
$72.3M
Q2 25
$28.9B
$72.1M
Q1 25
$28.0B
$72.0M
Q4 24
$27.5B
$71.8M
Q3 24
$27.2B
$71.7M
Q2 24
$26.8B
$71.6M
Q1 24
$26.8B
$29.9M
Stockholders' Equity
AGM
AGM
TARS
TARS
Q4 25
$1.7B
$343.4M
Q3 25
$1.7B
$335.1M
Q2 25
$1.5B
$332.6M
Q1 25
$1.5B
$342.5M
Q4 24
$1.5B
$224.5M
Q3 24
$1.5B
$237.5M
Q2 24
$1.5B
$252.2M
Q1 24
$1.5B
$275.2M
Total Assets
AGM
AGM
TARS
TARS
Q4 25
$35.4B
$562.2M
Q3 25
$33.4B
$534.6M
Q2 25
$33.0B
$495.0M
Q1 25
$31.8B
$500.8M
Q4 24
$31.3B
$377.0M
Q3 24
$30.6B
$376.3M
Q2 24
$30.2B
$376.8M
Q1 24
$29.8B
$349.3M
Debt / Equity
AGM
AGM
TARS
TARS
Q4 25
17.93×
0.21×
Q3 25
17.31×
0.22×
Q2 25
18.70×
0.22×
Q1 25
18.39×
0.21×
Q4 24
18.48×
0.32×
Q3 24
18.60×
0.30×
Q2 24
17.87×
0.28×
Q1 24
18.11×
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AGM
AGM
TARS
TARS
Operating Cash FlowLast quarter
$80.1M
$19.3M
Free Cash FlowOCF − Capex
$13.0M
FCF MarginFCF / Revenue
8.6%
Capex IntensityCapex / Revenue
0.0%
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AGM
AGM
TARS
TARS
Q4 25
$80.1M
$19.3M
Q3 25
$74.2M
$18.3M
Q2 25
$-47.7M
$-29.4M
Q1 25
$-49.8M
$-20.7M
Q4 24
$612.6M
$-22.2M
Q3 24
$-44.4M
$-8.7M
Q2 24
$56.1M
$-14.4M
Q1 24
$233.3M
$-37.8M
Free Cash Flow
AGM
AGM
TARS
TARS
Q4 25
$13.0M
Q3 25
$16.3M
Q2 25
$-30.4M
Q1 25
$-21.2M
Q4 24
$607.4M
$-22.3M
Q3 24
$-44.4M
$-8.9M
Q2 24
$52.6M
$-15.4M
Q1 24
$231.7M
$-38.0M
FCF Margin
AGM
AGM
TARS
TARS
Q4 25
8.6%
Q3 25
13.8%
Q2 25
-29.6%
Q1 25
-27.1%
Q4 24
599.8%
-33.5%
Q3 24
-49.2%
-18.6%
Q2 24
58.5%
-37.8%
Q1 24
247.3%
-137.5%
Capex Intensity
AGM
AGM
TARS
TARS
Q4 25
0.0%
4.2%
Q3 25
0.0%
1.6%
Q2 25
0.0%
1.0%
Q1 25
0.0%
0.8%
Q4 24
5.2%
0.1%
Q3 24
0.1%
0.6%
Q2 24
4.0%
2.5%
Q1 24
1.7%
0.6%
Cash Conversion
AGM
AGM
TARS
TARS
Q4 25
Q3 25
1.35×
Q2 25
-0.87×
Q1 25
-1.00×
Q4 24
10.84×
Q3 24
-0.89×
Q2 24
1.19×
Q1 24
4.34×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons